Principal Investigator/Program Director(Last. First Middle): Guay-WoodfOfd, LJS3 M. DESCRIPTION: See instructions. Statethe application's broad, long-termobjectives and specific aims,making referenceto the health relatedness of the project(i.e., relevance to the mission of the agency). Describe concisely the researchdesign and methods for achieving these goals. Describe the rationale and techniques you will use to pursuethese goals. In addition, in two or three sentences, describe in plain, lay languagethe relevance of this researchto public health. If the application is funded, this description, as is, will become public information. Therefore, do not include proprietary/confidential information. DO NOT EXCEEDTHE SPACE PROVIDED. n 2007, the University of Alabama at Birmingham (DAB) and its affiliates completed three important, large- scale strategic planning efforts. Together, these processes generated a """"""""blueprint for our research future"""""""" :hat lays the foundation to transform our substantial clinical and translational research enterprise through ntegration and innovation across all disciplines, Schools, and our health care system. This transformation will be driven by the DAB Center for Clinical and Translational Science (CCTS). The CCTS vision is to transform the DAB environment by building productive and efficient interdisciplinary research teams through educational ingenuity, regulatory reorganization, resource coordination, and methodological innovation. The mission is to develop a transformative infrastructure that spans the spectrum from preclinical research to bench-to-bedside translation (T1 research) to community implementation (T2 research), and will meet 5 goals: 1) transform the Investigator;2) transform the Training Environment;3) transform the Resource Infrastructure;4) transform the Approach to Interdisciplinary Research via an emphasis on outcomes research and health disparities research;and 5) establish a new Research Model through the Self-Monitoring and Improvement Program. To meet these goals, the CCTS will rely on: 1) a re-organized reporting structure that assures the PI full institutional support in implementing the CCTS roadmap;2) a revised CCTS leadership that includes faculty from the Schools of Medicine, Public Health, Nursing, Health Professions, and Optometry;and 3) innovative partnerships involving UAB, Southern Research Institute (ouraffiliated, not-for-profit research organization for preclinical drug discovery/development), the Children's Health System, the HudsonAlpha Institute for Biotechnology, the greater Birmingham community, and a long-standing collaborative network that involves Historically Black Colleges and Universities (HBCUs) and underprivileged communities in our region. UAB, the Health System, Health Services Foundation, Research Foundation, and Southern Research Institute have made substantial commitments to the CCTS including: 1) significant new funding for the clinical and translational research infrastructure (~$150 million, of which over $18 million are directly for CCTS activities and programs);2) a redesigned and enhanced biomedical informatics infrastructure;and 3) over 20,000 sf of prime clinical and administrative space. When combined, the re-organized CCTS governance and leadership, the substantial commitment of funds and resources, the interdisciplinary culture of UAB, and the new CCTS programs, will create a transformed environment for clinical and translational research that will benefit our trainees, investigators, patients, community, and the national CTSA effort.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
5UL1RR025777-04
Application #
8094441
Study Section
Special Emphasis Panel (ZRR1-SRC (99))
Program Officer
Sawczuk, Andrea
Project Start
2008-05-19
Project End
2013-04-30
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
4
Fiscal Year
2011
Total Cost
$4,931,201
Indirect Cost
Name
University of Alabama Birmingham
Department
Genetics
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Sarmiento, Elisa J; Moore, Justin Xavier; McClure, Leslie A et al. (2018) Fine Particulate Matter Pollution and Risk of Community-Acquired Sepsis. Int J Environ Res Public Health 15:
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Meredith, Ruby F; Torgue, Julien J; Rozgaja, Tania A et al. (2018) Safety and Outcome Measures of First-in-Human Intraperitoneal ? Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. Am J Clin Oncol 41:716-721
Dutta, Shilpa; Lopez Charcas, Osbaldo; Tanner, Samuel et al. (2018) Discovery and evaluation of nNav1.5 sodium channel blockers with potent cell invasion inhibitory activity in breast cancer cells. Bioorg Med Chem 26:2428-2436
McKenzie, Katelyn A; El Ters, Mirelle; Torres, Vicente E et al. (2018) Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort. BMC Nephrol 19:378
Akinyemiju, Tomi; Moore, Justin Xavier; Pisu, Maria et al. (2018) A Prospective Study of Obesity, Metabolic Health, and Cancer Mortality. Obesity (Silver Spring) 26:193-201
Akinyemiju, Tomi; Moore, Justin Xavier; Judd, Suzanne E et al. (2018) Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality. Oncotarget 9:16099-16109
Moore, Justin Xavier; Akinyemiju, Tomi; Bartolucci, Alfred et al. (2018) Mediating Effects of Frailty Indicators on the Risk of Sepsis After Cancer. J Intensive Care Med :885066618779941
Hsu, Joann; Donnelly, John P; Chaudhary, Ninad S et al. (2018) Aspirin use and long-term rates of sepsis: A population-based cohort study. PLoS One 13:e0194829
Yu, Alan S L; Shen, Chengli; Landsittel, Douglas P et al. (2018) Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int 93:691-699

Showing the most recent 10 out of 311 publications